Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
190 hedge funds and large institutions have $5.5B invested in Mirati Therapeutics, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 69 increasing their positions, 62 reducing their positions, and 28 closing their positions.
117% more call options, than puts
Call options by funds: $232M | Put options by funds: $107M
67% more funds holding in top 10
Funds holding in top 10: 6 → 10 (+4)
64% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 28
64% more capital invested
Capital invested by funds: $3.36B → $5.5B (+$2.14B)
11% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 62
7% more funds holding
Funds holding: 177 → 190 (+13)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$77.7M |
| 2 |
Sands Capital Management
Arlington,
Virginia
|
+$45.4M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$42.9M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$32M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$27.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$46.4M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$34.5M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$33.6M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$30.6M |
| 5 |
Renaissance Technologies
New York
|
-$28.3M |
MRTX Hedge Fund Activity: Q4 2019 in Review
190 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q4 2019, worth a combined $5.5B — up 64% from $3.36B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new MRTX positions and 28 closed out — a net gain of 18 holders — while 69 added to existing stakes and 62 trimmed.
The largest buyer was OrbiMed, adding an estimated $77.7M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $46.4M sold.
- 190 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q4 2019, up from 177 in Q3 2019.
- Funds reported $5.5B of Mirati Therapeutics, Inc. Common Stock stock for Q4 2019, up 64% quarter-over-quarter.
- 46 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q4 2019 and 28 closed out, a net change of +18 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q4 2019 was OrbiMed, an estimated $77.7M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q4 2019 was Point72 Asset Management, an estimated $46.4M sold.
Based on aggregated 13F filings for Q4 2019.